Archive for October, 2007

Experts call for autism checkups for tots by 2

As reported in this week by the Arizona Republic:

The country’s leading pediatricians group is making its strongest push yet to have all children screened for autism twice by age 2, warning of symptoms such as babies who don’t babble at 9 months and 1-year-olds who don’t point to toys.

The advice is meant to help parents and doctors spot autism sooner. There is no cure for the disorder, but experts say that early therapy can lessen its severity.

Symptoms to watch for and the call for early screening come in two new reports. They are being released today by the American Academy of Pediatrics at its annual meeting in San Francisco and will appear in the November issue of the journal Pediatrics and on the group’s Web site: www.aap.org.

The reports list numerous warning signs, such as a 4-month-old not smiling at the sound of Mom or Dad’s voice, or the loss of language or social skills at any age.

Experts say one in 150 U.S. children have the troubling developmental disorder.

Lindsey Tanner
Associated Press
Oct. 29, 2007 12:00 AM

For additional information on autism and autism nutrition please visit: www.awakennutrition.com

Source: http://www.azcentral.com/news/articles/1029A1autism1029.html

Comments

Chelation Therapy: Is PCA-Rx the answer?

Chelation therapy is used as a treatment for acute mercury, iron, arsenic, lead, uranium and other toxic metal poisoning. Chelation functions by making a chemical bond with the metal ions rendering them inactive and allowing the metal to be excreted naturally from the body. The medical community has regularly used chelation therapy since the early 1960’s to treat lead poisoning in military personnel and other heavy metal poisoning. This process is done through intravenous injection using dimercaptosuccinic acid (DMSA), dimercaptopropane sulfonate (DMPS), or ethylene diaminetetraacetic acid (EDTA).

Oral Chelation therapies are available as an alternative to the intravenous option. Agents such as PCA-Rx, a breakthrough peptide clathration formula have shown to effectively clear heavy metals, toxins, plaque, pesticides, chemicals, and residuals from prior bacterial and viral infections. It has also been shown effective for the treatment of heart disease, and the treatment of children with autism.

PCA-Rx acts as a clathration formula which encloses the toxin using three different types of irreversible bonds. These bonds attach to and completely envelop the toxin, neutralzing it, and keep it from coming into contact with any other bodily tissues and is naturally expelled from the body through urination. This method is especially effective against heavy metals.

Practitioners claim that the exposure to heavy metals in the environment and through childhood vaccinations have contributed to the poisoning of the body and may have led to the development of autism. Those who have been exposed to pesticides, lead paints or mercury through dental amalgam fillings or thimerosal and ethyl-mercury used in childhood vaccinations are most at risk. Some in the medical community have discovered the benefits of using chelation treatment for heart disease believing that the chelation agent forms a complex with the calcium in the walls of the arteries allowing it to build up and cause hardening of the arteries which can lead to heart disease.

Oral Chelation agents such as PCA-Rx, are available to treat children with autism and people with other
disorders, however, no treatment is a replacement for medical attention from a licensed practitioner. Always ask your doctor before taking any kind of treatment or nutritional supplement. For more information on chelation and PCA-Rx please visit: www.awakennutrition.com

Comments

First autism genome scan is completed

Good news on the front lines of autism research, scientists have completed the first genome scan for autism. This exciting news will help to understand autism and the most effective treatments for autism. See article below:

BOSTON, Oct. 23 (UPI) — A U.S. group of scientists has completed and released the first genome scan for autism spectrum disorders for use by researchers around the world.

The Autism Consortium, a group of researchers, clinicians and families dedicated to radically accelerating research and enhancing clinical care for autism, said the scan was conducted using new, high-resolution technology on genetic data from more than 3,000 children with ASD and their families.

The release of genetic and phenotypic autism data marks a significant achievement, said Thomas Insel, director of the National Institute for Mental Health.

“Progress in finding the causes and cures for autism spectrum disorders rests in large part on improving the rapid access and sharing of data and resources,” said Insel. “That the consortium is making the data available to the scientific community even before its own researchers have fully analyzed the information, demonstrates their high degree of commitment to and leadership in advancing autism research.”

Officials said the new data provide the most detailed look to date at the genetic variation patterns in families with autism.

Researchers conducted the genome wide study using GeneChip microarray technology made by Affymetrix Inc, of Santa Clara, Calif.

Published: 23, 2007 at 11:03 AM

Source: http://www.upi.com

Comments

Catching autism early

Screening, treatment center to open on Florida Tech’s campus in 2009. Florida Tech is hosting an Autism Conference on Oct. 18 and 19 for educators, health care and social service providers, and families. A positive step in promoting the early detection and treatment options for Autism. See full article from “Florida Today” below:

“One of triplets, Nicholas Diaz began falling behind his brothers, developmentally, as early as 8 months of age, according to his mother, Dee Dee.

“There were big delays in crawling, talking and eye contact, even then,” she said.

But, because of other medical problems associated with entering the world two months prematurely, she said, Nicholas did not get an official autism diagnosis until about 21/2 years ago.

Today, at age 5, the Palm Bay boy goes to a small clinic on the Florida Tech campus, where he undergoes applied behavioral analysis, a highly structured therapy that rewards him for learning language and social skills appropriate to his age, so he can eventually attend regular school.

“I am seeing a huge difference,” his mother said, citing better word recognition, among other new skills, even though Nicholas still rarely speaks. “Applied behavioral analysis is the most research-proven therapy we have.”

By spring 2009, Florida Tech in Melbourne plans to showcase this intervention for as many as 30 to 40 other individuals every week in a new 18,000-square-foot Autism Center, to be built on campus, starting next year. Estimated cost: about $4.5 million.

Although most of those undergoing treatment will be children Nicholas’ age or younger, university officials said, the center will serve individuals across the life span with autism, a spectrum of disorders that cause substantial impairments in social interaction and communication, along with odd behaviors and peculiarly intense interests.

As part of the school’s mission to develop this comprehensive new autism resource, Florida Tech is hosting an Autism Conference on Oct. 18 and 19 for educators, health care and social service providers, and families.

“We want to educate the public about autism and the types of treatments that are known to be the most effective,” said Mary Beth Kunkel, dean of the College of Psychology and Liberal Arts. “One of the hallmarks for our center is we are committed only to treatments with empirical support.”

That means the university does not intend to offer still-controversial biomedical therapies some parents swear by, such as nutrition and vitamin supplementation; chelation therapy to remove mercury and other metals from the blood; and hyperbaric oxygen, to improve circulation to every area of the body, including the brain.

Nor, Kunkel said, will there be any talks about thimerosal, the mercury-based preservative once routinely put in children’s vaccines, but now a rarity, which remains at the heart of a fierce debate over its role in autism’s development.

“Research tells us now mercury is not related to autism, but it is still an issue with some parents,” she conceded. “It’s a major controversy.”

1 in 150 affected

By existing standards, autism spectrum disorders in the United States are the second most serious developmental disability after mental retardation, affecting about 1 in 150 children, according to the Centers for Disease Control and Prevention in Atlanta.

Because prevalence is clearly on the rise, and no one yet knows the cause, “everybody is concerned,” Kunkel said. “But our real focus is, if you have a loved one with autism, what are you going to do?”

Eb Blakely, a behavioral analyst with the nonprofit Quest Inc. in Orlando, and one of the conference speakers, said he intends to address that question in his talk, “Autism and the Scientific Method.”

“What I hope to do is help people figure out what to do with their kid if he or she is diagnosed with autism,” he said. “It’s complex. You need to ask: Is there any research on a (particular) treatment, and if there is, what kind is it?”

To illustrate his point, Blakely plans to use a case study, involving hormone-replacement therapy, whose early promise in the 1980s and 1990s arose out of “weak” observational studies, he said, rather than the gold standard — controlled, randomized trials.

As a result, in 2003, the government abruptly halted a major study in postmenopausal women after it was found this therapy increased, rather than lessened, the risks for heart attacks, breast cancers and stroke.

Of the various treatment approaches to autism, Blakely said, “it’s a difficult topic and I’m not taking any stands. Let the science speak for itself.”

The best-known study backing a behavior-based approach to autism dates to 1987, experts say.

Sixty children were randomly assigned at that time to several years of intensive therapy with one of three approaches, including applied behavioral analysis.

Rewards in this approach, often a toy or some type of social interaction, come as a child completes each task at his or her age level, based on performance.

The study found 47 percent of children who got the behavioral intervention were able to go back into regular classrooms, said David Wilder, an associate professor in Florida Tech’s psychology college.

“At the end of the study, they were indistinguishable from their peers,” he said. “And their IQ improved dramatically.

Like his colleagues, Wilder emphasized the importance of early intervention, however.

“The earlier we get to these kids, the better,” he said.

Alternative approaches

Despite her clear support for behavior-based therapy, Dee Dee Diaz said she and her husband also have taken Nicholas to the nonprofit International Child Development Research Center in Melbourne, run by Dr. Jeffrey Bradstreet, to try alternative therapies.

Bradstreet is a leading proponent of unproven biomedical therapies that enhance methylation, a process critical to normal cell function and nerve development and overall immune responses.

Nicholas not only eats a restricted diet, his mother said, he also has undergone chelation therapy and hyperbaric oyxgen treatments at Bradstreet’s center — both of which appeared to bring some benefit.

“From a parent’s perspective, we try one thing out at a time,” she said. “When you see your child turn around and suddenly say a few words, it’s monumental.”

As an elementary school teacher and an educator, she added, “I think hard science is wonderful,” but parents worry, if they wait 20 years for the science, “their children may be so far out into their own world by then, nobody will be able to help them.”


BY SUSAN JENKS
FLORIDA TODAY

Comments